User profiles for RM Huber

Rudolf Huber

University of Munich
Verified email at med.uni-muenchen.de
Cited by 22183

[HTML][HTML] International association for the study of lung cancer/american thoracic society/european respiratory society international multidisciplinary classification of …

…, FR Hirsch, G Scagliotti, T Mitsudomi, RM Huber… - Journal of thoracic …, 2011 - Elsevier
Introduction: Adenocarcinoma is the most common histologic type of lung cancer. To
address advances in oncology, molecular biology, pathology, radiology, and surgery of lung …

Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate …

…, A Lopez-Chavez, C Grohe, RM Huber… - The lancet …, 2015 - thelancet.com
Background Patients with squamous non-small-cell lung cancer that is refractory to multiple
treatments have poor outcomes. We assessed the activity of nivolumab, a fully human IgG4 …

ERS/ESTS clinical guidelines on fitness for radical therapy in lung cancer patients (surgery and chemo-radiotherapy)

…, MK Ferguson, C Faivre-Finn, RM Huber… - European …, 2009 - Eur Respiratory Soc
A collaboration of multidisciplinary experts on the functional evaluation of lung cancer
patients has been facilitated by the European Respiratory Society (ERS) and the European …

Brigatinib in patients with crizotinib-refractory anaplastic lymphoma kinase–positive non–small-cell lung cancer: a randomized, multicenter phase II trial

…, KH Hansen, SW Kim, RM Huber… - Journal of Clinical …, 2017 - ascopubs.org
Purpose Most crizotinib-treated patients with anaplastic lymphoma kinase gene (ALK)–rearranged
non–small-cell lung cancer (ALK-positive NSCLC) eventually experience disease …

Combined transcriptome and genome analysis of single micrometastatic cells

…, N Wendler, B Passlick, RM Huber… - Nature …, 2002 - nature.com
In human cancer, early systemic spread of tumor cells is recognized as a leading cause of
death. Adjuvant therapies are administered to patients after complete resectioning of their …

Place of cryotherapy, brachytherapy and photodynamic therapy in therapeutic bronchoscopy of lung cancers

JM Vergnon, RM Huber… - European Respiratory …, 2006 - Eur Respiratory Soc
Cryotherapy, brachytherapy and photodynamic therapy (PDT) are three different methods
proposed in the endoluminal treatment of lung cancers. The current article presents an …

Management of patients with idiopathic pulmonary fibrosis in clinical practice: the INSIGHTS-IPF registry

…, S Gläser, FJF Herth, T Welte, RM Huber… - European …, 2015 - Eur Respiratory Soc
After introduction of the new international guidelines on idiopathic pulmonary fibrosis (IPF)
in 2011, we investigated clinical management practices for patients with IPF according to …

Autofluorescence bronchoscopy with white light bronchoscopy compared with white light bronchoscopy alone for the detection of precancerous lesions: a European …

…, F Herth, M Kohlhäufl, KM Müller, RM Huber… - Thorax, 2005 - thorax.bmj.com
Background: The potential of autofluorescence bronchoscopy (AFB) to detect precancerous
lesions in the central airways and its role in lung cancer screening is uncertain. A study was …

[HTML][HTML] Efficacy of the irreversible ErbB family blocker afatinib in epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI)–pretreated non–small-cell …

…, J Stöhlmacher-Williams, A Märten, RM Huber… - Journal of Thoracic …, 2015 - Elsevier
Introduction Afatinib is an effective first-line treatment in patients with epidermal growth factor
receptor (EGFR)-mutated non–small-cell lung cancer (NSCLC) and has shown activity in …

Generation of multiple farnesoid-X-receptor isoforms through the use of alternative promoters

RM Huber, K Murphy, B Miao, JR Link… - Gene, 2002 - Elsevier
Bile acid biosynthesis is regulated by both feed-forward and feedback mechanisms involving
a cascade of nuclear hormone receptors. Feed-forward regulation of the rate limiting …